A non-interventional, case-control, screening and outcomes study of tipifarnib in patients with head and neck squamous cell carcinomas (HNSCC) with HRAS mutations

Trial Profile

A non-interventional, case-control, screening and outcomes study of tipifarnib in patients with head and neck squamous cell carcinomas (HNSCC) with HRAS mutations

Planning
Phase of Trial: Phase III

Latest Information Update: 15 Mar 2018

At a glance

  • Drugs Tipifarnib (Primary)
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Acronyms SEQ-HN
  • Most Recent Events

    • 15 Mar 2018 New trial record
    • 12 Mar 2018 According to a Kura Oncology media release, the company plans to initiate this study in the first half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top